{"content":[{"text":"Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at \n the European Hematology Association Congress 2021","bbox":{"left":0.085882,"top":0.138678,"width":0.828189,"height":0.049211000000000005}},{"text":"- Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 in AL amyloidosis - \n - Phase 3 studies of CAEL-101 in AL amyloidosis are underway -","bbox":{"left":0.115529,"top":0.207098,"width":0.769144,"height":0.037773999999999974}},{"text":"BORDENTOWN, N.J. & BOSTON, MA – MAY 12, 2021 – Caelum Biosciences and Alexion Pharmaceuticals, Inc. \n (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a potentially first-in-class amyloid fibril \n targeted therapy, have been accepted for e-poster presentation at the European Hematology Association (EHA) \n Congress 2021, taking place virtually from June 9 to 17, 2021. Both presentations will include new data from \n the Phase 2 open-label dose escalation study evaluating the safety and tolerability of CAEL-101 in combination \n with standard-of-care therapy in AL amyloidosis. One will feature data studying safety and tolerability in AL \n amyloidosis patients treated with 1000 mg/m2 CAEL-101 in combination with cyclophosphamide-bortezomib- \n dexamethasone plus daratumumab. The second will include new data further supporting the selection of the \n 1000 mg/m2 dose for the ongoing Phase 3 study and demonstrating the possible stabilization of cardiac disease \n as assessed by Mayo staging.","bbox":{"left":0.081765,"top":0.270166,"width":0.837137,"height":0.18583}},{"text":"The abstracts accepted for e-poster presentations are listed below and are now available on the EHA website. \n All e-poster presentations will be made available on the virtual congress platform on June 11, 2021 at 09:00 \n a.m. CEST (3:00 a.m. EDT) and will be available throughout the duration of the Congress.","bbox":{"left":0.081765,"top":0.477919,"width":0.837026,"height":0.053683000000000036}},{"text":"Safety and Tolerability of CAEL-101 in Combination with Cyclophosphamide-Bortezomib-Dexamethasone and \n Daratumumab in Patients with AL Amyloidosis. Abstract #EP1017– e-poster presentation; session title: \n Myeloma and other monoclonal gammopathies – Clinical.","bbox":{"left":0.081765,"top":0.553525,"width":0.816385,"height":0.053683000000000036}},{"text":"Safety and Tolerability of CAEL-101 in Patients with AL Amyloidosis in a Phase 2 Study for a Median of 38 Weeks. \n Abstract #EP1018 – e-poster presentation; session title: Myeloma and other monoclonal gammopathies – \n Clinical.","bbox":{"left":0.081765,"top":0.629169,"width":0.837026,"height":0.053683000000000036}},{"text":"As was previously announced, the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical \n program to evaluate CAEL-101 in combination with SoC therapy in AL amyloidosis has begun. Enrollment is \n underway in two parallel Phase 3 studies – one in patients with Mayo stage IIIa disease (ClinicalTrials.gov \n Identifier: NCT04512235) and one in patients with Mayo stage IIIb disease (ClinicalTrials.gov Identifier: \n NCT04504825) – and will collectively enroll approximately 370 patients globally. The Phase 2 program \n continues with the ongoing evaluation of CAEL-101 in combination with SoC therapy plus daratumumab.","bbox":{"left":0.081765,"top":0.704775,"width":0.8368840000000001,"height":0.11034900000000003}},{"text":"About CAEL-101 \n CAEL-101 is a first-in-class monoclonal antibody (mAb) designed to improve organ function by reducing or \n eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. The antibody is designed \n to bind to misfolded light chain protein and amyloid and shows binding to both kappa and lambda subtypes. In \n a Phase 1a/1b study, CAEL-101 demonstrated improved organ function, including cardiac and renal function, in","bbox":{"left":0.081765,"top":0.837073,"width":0.8365960000000001,"height":0.0914100000000001}},{"text":"1","bbox":{"left":0.494788,"top":0.948437,"width":0.010579000000000005,"height":0.01580400000000004}}],"images_bbox":[{"left":0.292075,"top":0.054293,"width":0.187059,"height":0.080871},{"left":0.479167,"top":0.065025,"width":0.228758,"height":0.070707}],"images_bbox_not_text_overlap":[{"left":0.292075,"top":0.054293,"width":0.187059,"height":0.080871},{"left":0.479167,"top":0.065025,"width":0.228758,"height":0.070707}]}